Annette Langer-Gould to Rituximab
This is a "connection" page, showing publications Annette Langer-Gould has written about Rituximab.
Connection Strength
5.661
-
Anti-NMDA receptor encephalitis outcomes in a population-based cohort. J Neurol. 2026 Jul 15; 273(8).
Score: 0.954
-
De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy. Mult Scler. 2026 Apr; 32(4):409-420.
Score: 0.933
-
Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 2026 Jan 27; 106(2):e214473.
Score: 0.918
-
Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021 04; 8(4):938-943.
Score: 0.661
-
Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
Score: 0.621
-
Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections. Neurol Neuroimmunol Neuroinflamm. 2024 May; 11(3):e200211.
Score: 0.203
-
Rituximab for Multiple Sclerosis: Hiding in Plain Sight Neurology. 2024 01 23; 102(2):e208063.
Score: 0.200
-
Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023 Nov; 10(6).
Score: 0.197
-
Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. JAMA Netw Open. 2022 12 01; 5(12):e2248664.
Score: 0.186
-
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw Open. 2021 12 01; 4(12):e2136697.
Score: 0.173
-
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
Score: 0.160
-
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 05; 87(5):688-699.
Score: 0.154
-
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020 02 01; 77(2):184-191.
Score: 0.153
-
Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol. 2009 Jun; 29(2):104-6.
Score: 0.073
-
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020 07 02; 7(4).
Score: 0.039
-
Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler. 2012 Mar; 18(3):377-8.
Score: 0.021
-
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7):676-88.
Score: 0.017